BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target
BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $8 price target.
Stocks · News reference
Acumen Announces New Findings Presented At AAIC 2026; JCR Collaboration Shows Improved Brain Penetration Of Anti‑Aβo Antibodies Via Transferrin Receptor Delivery In Mouse And Primate Models
EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may enable administration with a low-volume delivery device and reduce the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Acumen Pharmaceuticals, Inc. (ABOS)
Filed: 2026-09-16 AccNo: 0001628280-26-062137 Size: 8 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
Acumen Pharmaceuticals announced a virtual Investor Day scheduled for September 16, 2026, to discuss its clinical-stage pipeline. The company is advancing sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers for Alzheimer's disease treatment, with Phase 2 ALTITUDE-AD trial results expected in late 2026. Acumen is also exploring subcutaneous formulations and collaborating with JCR Pharmaceuticals on enhanced brain delivery technologies.
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Acumen Pharmaceuticals announced that management will participate in two upcoming investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and Citi's 2026 Biopharma Back to School Conference on September 10. The company is advancing its lead candidate sabirnetug (ACU193) in Phase 2 trials for early symptomatic Alzheimer's disease and expects to report topline results in late 2026.